JP4808785B2 - インスリン組成物および組成物の製造方法 - Google Patents

インスリン組成物および組成物の製造方法 Download PDF

Info

Publication number
JP4808785B2
JP4808785B2 JP2008547953A JP2008547953A JP4808785B2 JP 4808785 B2 JP4808785 B2 JP 4808785B2 JP 2008547953 A JP2008547953 A JP 2008547953A JP 2008547953 A JP2008547953 A JP 2008547953A JP 4808785 B2 JP4808785 B2 JP 4808785B2
Authority
JP
Japan
Prior art keywords
insulin
ethoxy
human insulin
acylated
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008547953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522231A (ja
JP2009522231A5 (enExample
Inventor
スヴェンド ハヴェルンド，
フランチセク フバレク，
ヘレ， ビルク オルセン，
イブ ヨナセン，
トマス ヘーグ−イェンセン，
アンネ プラム，
ウラ リベル−マドセン，
Original Assignee
ノボ・ノルデイスク・エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4808785(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノボ・ノルデイスク・エー／エス filed Critical ノボ・ノルデイスク・エー／エス
Publication of JP2009522231A publication Critical patent/JP2009522231A/ja
Publication of JP2009522231A5 publication Critical patent/JP2009522231A5/ja
Application granted granted Critical
Publication of JP4808785B2 publication Critical patent/JP4808785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008547953A 2005-12-28 2006-12-21 インスリン組成物および組成物の製造方法 Active JP4808785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05113021 2005-12-28
EP05113021.9 2005-12-28
PCT/EP2006/070104 WO2007074133A2 (en) 2005-12-28 2006-12-21 Compositions comprising an acylated insulin and zinc and method of making the said compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010174030A Division JP5026567B2 (ja) 2005-12-28 2010-08-02 インスリン組成物および組成物の製造方法
JP2011008924A Division JP2011121963A (ja) 2005-12-28 2011-01-19 インスリン組成物および組成物の製造方法

Publications (3)

Publication Number Publication Date
JP2009522231A JP2009522231A (ja) 2009-06-11
JP2009522231A5 JP2009522231A5 (enExample) 2010-09-16
JP4808785B2 true JP4808785B2 (ja) 2011-11-02

Family

ID=36888823

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008547953A Active JP4808785B2 (ja) 2005-12-28 2006-12-21 インスリン組成物および組成物の製造方法
JP2010174030A Active JP5026567B2 (ja) 2005-12-28 2010-08-02 インスリン組成物および組成物の製造方法
JP2011008924A Withdrawn JP2011121963A (ja) 2005-12-28 2011-01-19 インスリン組成物および組成物の製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010174030A Active JP5026567B2 (ja) 2005-12-28 2010-08-02 インスリン組成物および組成物の製造方法
JP2011008924A Withdrawn JP2011121963A (ja) 2005-12-28 2011-01-19 インスリン組成物および組成物の製造方法

Country Status (10)

Country Link
US (2) US20090074882A1 (enExample)
EP (2) EP2505593A1 (enExample)
JP (3) JP4808785B2 (enExample)
CN (1) CN101389650B (enExample)
AT (1) ATE519780T1 (enExample)
DK (1) DK1969004T3 (enExample)
ES (1) ES2371361T3 (enExample)
PL (1) PL1969004T3 (enExample)
PT (1) PT1969004E (enExample)
WO (1) WO2007074133A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011121963A (ja) * 2005-12-28 2011-06-23 Novo Nordisk As インスリン組成物および組成物の製造方法
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051103A2 (en) * 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP2015770B1 (en) * 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
WO2007128815A1 (en) * 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
EP2217621B1 (en) * 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
BRPI0820535B8 (pt) * 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
MX2012012943A (es) * 2010-05-10 2012-11-29 Novo Nordisk As Proceso para preparacion de complejos de insulina-cinc.
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
WO2012104339A1 (en) * 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
EP2844274B1 (en) 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
CN105188736A (zh) * 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
MX2016008978A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
BR112017018060A2 (pt) 2015-02-25 2018-04-10 Dance Biopharm Inc formulação de insulina, dose de unidade, e, método de tratar um indivíduo com diabetes melito.
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
WO2018024186A1 (zh) * 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
JP2021512124A (ja) * 2018-02-01 2021-05-13 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヒトインスリンアナログのアシル化誘導体を含有する医薬組成物及びその調製方法
EP3805257A4 (en) 2018-05-24 2022-03-16 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF PRODUCTION OF A PRECURSOR OF RECOMBINANT HUMAN INSULIN OR ANALOGUE THEREOF
CN113045473A (zh) * 2020-03-18 2021-06-29 广东东阳光药业有限公司 制备长脂肪链二酸衍生物的方法及其应用
TW202229324A (zh) * 2020-11-27 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 製備胰島素或其類似物的醯化衍生物的方法
AU2022300061A1 (en) * 2021-06-25 2024-02-01 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
US20230025595A1 (en) * 2021-07-13 2023-01-26 America Great Health, a California Corporation Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
JP2002527487A (ja) * 1998-10-16 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 肺送達のための安定に濃縮されたインスリン製剤
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
JP2004523589A (ja) * 2001-03-23 2004-08-05 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 改善された安定性を有するいかなる量の亜鉛も含有しないかまたはほんの少量の亜鉛しか含有しないインスリン製剤
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3907676A (en) 1970-07-28 1975-09-23 Novo Terapeutisk Labor As Process for purifying insulin
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4876322A (en) 1984-08-10 1989-10-24 Siemens Aktiengesselschaft Irradiation cross-linkable thermostable polymer system, for microelectronic applications
EP0174493B1 (de) 1984-08-17 1988-05-25 Bayer Ag Thermoplastische Formmassen mit flammwidrigen Eigenschaften
DE3433367A1 (de) 1984-09-12 1986-03-20 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS61226115A (ja) 1985-03-30 1986-10-08 Mitsubishi Metal Corp 線条体押し出し機
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
DK45590D0 (enExample) 1990-02-21 1990-02-21 Novo Nordisk As
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
DE69232847T2 (de) 1991-12-20 2003-09-11 Novo Nordisk A/S, Bagsvaerd Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CZ289343B6 (cs) 1995-03-17 2002-01-16 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
ATE278711T1 (de) 1996-07-11 2004-10-15 Novo Nordisk As Verfahren zur selektiven acetylierung
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
JP2001518916A (ja) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ 結晶インスリンを含有する肺投与のための治療用粉末調合物
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
RU2218349C2 (ru) 1997-10-24 2003-12-10 Ново Нордиск А/С Агрегаты производных инсулина человека
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
WO2000043034A2 (en) * 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
JP2002543092A (ja) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
JP4624600B2 (ja) * 2001-06-08 2011-02-02 トヨタ自動車株式会社 焼結合金、その製造方法およびバルブシート
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
AU2003208316A1 (en) * 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
RU2329823C2 (ru) 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
CN1771040B (zh) 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药
CN100422328C (zh) 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135
BRPI0408105A (pt) 2003-03-04 2006-03-01 Thetechnology Dev Company Ltd sistema de distribuição para droga e terapia celular
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
DK2275439T3 (da) 2003-08-05 2014-05-12 Novo Nordisk As Hidtil ukendte insulinderivater
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
WO2005063298A1 (en) 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
CA2567309A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
CA2576519C (en) 2004-08-17 2013-05-21 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
CA2593112A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP2012817A2 (en) 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
EP2015770B1 (en) * 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
WO2007135117A2 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2217621B1 (en) 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
BRPI0820535B8 (pt) * 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
MX2012012943A (es) 2010-05-10 2012-11-29 Novo Nordisk As Proceso para preparacion de complejos de insulina-cinc.
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
WO2012104339A1 (en) 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
EP4070801A1 (en) 2011-03-01 2022-10-12 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP2798546B1 (en) 2011-09-13 2020-12-23 Novo Nordisk A/S Adaptive system for optimizing a drug dosage regimen over time
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
EP2844274B1 (en) 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
CN105188736A (zh) 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US10919949B2 (en) 2017-08-17 2021-02-16 Novo Nordisk A/S Acylated insulin analogues and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
JP2002527487A (ja) * 1998-10-16 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 肺送達のための安定に濃縮されたインスリン製剤
JP2004523589A (ja) * 2001-03-23 2004-08-05 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 改善された安定性を有するいかなる量の亜鉛も含有しないかまたはほんの少量の亜鉛しか含有しないインスリン製剤
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
JP2011121963A (ja) * 2005-12-28 2011-06-23 Novo Nordisk As インスリン組成物および組成物の製造方法
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12226458B2 (en) 2018-06-26 2025-02-18 Novo Nordisk A/S System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Also Published As

Publication number Publication date
US20140328943A1 (en) 2014-11-06
PL1969004T3 (pl) 2012-01-31
EP1969004B1 (en) 2011-08-10
JP2011121963A (ja) 2011-06-23
CN101389650A (zh) 2009-03-18
PT1969004E (pt) 2011-11-25
DK1969004T3 (da) 2011-11-28
JP2009522231A (ja) 2009-06-11
US11167035B2 (en) 2021-11-09
JP2011006428A (ja) 2011-01-13
ES2371361T3 (es) 2011-12-30
EP1969004A2 (en) 2008-09-17
EP2505593A1 (en) 2012-10-03
JP5026567B2 (ja) 2012-09-12
CN101389650B (zh) 2012-10-10
ATE519780T1 (de) 2011-08-15
US20090074882A1 (en) 2009-03-19
WO2007074133A3 (en) 2007-10-11
WO2007074133A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
JP4808785B2 (ja) インスリン組成物および組成物の製造方法
JP2009522231A5 (enExample)
EP2256129B1 (en) Insulin derivatives
JP5721432B2 (ja) アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
EP2262539B1 (en) Insulin albumin conjugates
JP5550338B2 (ja) ペグ化持続型インスリン
JP5730569B2 (ja) アシル及びアルキレングリコール部分を有するインスリンアナログ
CN102037008B (zh) 蛋白酶稳定化的、酰化胰岛素类似物
NO340925B1 (no) Nye insulinderivater
JP2013545782A (ja) 長時間作用型インスリンと組み合わせた速効型インスリン
EP2058330A1 (en) Insulin derivative

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091218

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100802

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100802

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110719

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110817

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140826

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4808785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140826

Year of fee payment: 3

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250